Regeneron Pharmaceuticals (REGN) Payables (2016 - 2025)
Regeneron Pharmaceuticals has reported Payables over the past 17 years, most recently at $939.0 million for Q4 2025.
- Quarterly results put Payables at $939.0 million for Q4 2025, up 18.94% from a year ago — trailing twelve months through Dec 2025 was $939.0 million (up 18.94% YoY), and the annual figure for FY2025 was $939.0 million, up 18.94%.
- Payables for Q4 2025 was $939.0 million at Regeneron Pharmaceuticals, up from $903.8 million in the prior quarter.
- Over the last five years, Payables for REGN hit a ceiling of $939.0 million in Q4 2025 and a floor of $427.0 million in Q3 2021.
- Median Payables over the past 5 years was $562.8 million (2021), compared with a mean of $611.1 million.
- Biggest five-year swings in Payables: plummeted 74.68% in 2021 and later skyrocketed 81.74% in 2025.
- Regeneron Pharmaceuticals' Payables stood at $564.0 million in 2021, then grew by 4.47% to $589.2 million in 2022, then grew by 2.95% to $606.6 million in 2023, then surged by 30.15% to $789.5 million in 2024, then grew by 18.94% to $939.0 million in 2025.
- The last three reported values for Payables were $939.0 million (Q4 2025), $903.8 million (Q3 2025), and $723.9 million (Q2 2025) per Business Quant data.